Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from...
Hence then, the article about tremfya guselkumab delivers sustained clinical and endoscopic remission in ulcerative colitis through two years was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years )
Also on site :
- ‘Neuromancer’ First Look: Callum Turner Is a Cyberspace Criminal in Teaser for Apple TV Sci-Fi Series
- Hayley Williams Brings Jenny Lewis, Jack Antonoff & More Surprise Guests to the Stage at Newport Folk Fest
- ‘Avengers: Doomsday’ Trailer Rocks Comic-Con: Doctor Doom Raises Army of Sentinels to Take Down Avengers, Fantastic Four and X-Men